Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

## FOSUNPHARMA 复星医药

## 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

## VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE MOVEMENT

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the "Company") voluntarily.

The board of directors (the "**Board**") of the Company has noted the decrease in the price of the shares of the Company (the "**Shares**") today. Having made all such enquiry with respect to the Company as is reasonable in the circumstances, the Company does not have any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The operations of the Company remain normal.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the Shares.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Chen Qiyu

Chairman

Shanghai, People's Republic of China 22 June 2017

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors of the Company are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

\* for identification purposes only